Cochrane's systematic review of MMR efficiency and safety. The vaccine efficacy is 95% against measles and 88% against mumps.
The vaccine increases the risk of aseptic meningitis by a factor of 14-22 (Urabe and Leningrad-Zagreb strains), the risk of febrile convulsions by a factor of 4-5.7, the risk of thrombocytopenic purpura by a factor of 2.4-6.3.
The authors conclude that clinical and post-clinical safety studies of MMR are largely inadequate and that it is not possible to separate the role of the vaccine in preventing disease from the side effects it causes.
They recommend improving the format and reporting of clinical and post-clinical trials, and standardizing the side effects definitions. It is also required to test the longevity of MMR protective effect.
Content above is licenced under Creative Common Attribution—NonCommercial—NoDerivatives (CC BY-NC-ND) licence,
